Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H25Cl2FN4O2 |
Molecular Weight | 491.385 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@H](COC3=CC4=NC=NC(NC5=C(F)C(Cl)=C(Cl)C=C5)=C4C=C3OC)C[C@]1([H])CN(C)C2
InChI
InChIKey=HVXKQKFEHMGHSL-QKDCVEJESA-N
InChI=1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)/t13-,14-,15+
DescriptionSources: http://adisinsight.springer.com/drugs/800020855Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/17575237
Sources: http://adisinsight.springer.com/drugs/800020855
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/17575237
Tesevatinib (EXEL-7647 or XL647) was optimized as an inhibitor of a spectrum of growth-promoting and angiogenic receptor tyrosine kinases (RTKs) to simultaneously block tumor growth and vascularization. In particular, Tesevatinib potently inhibits the EGF/ErbB2, VEGF, and ephrin RTK families. The drug is being developed by Kadmon Corporation under licence from Symphony Evolution (Symphony Capital Partners). Kadmon is developing tesevatinib for the treatment of autosomal polycystic kidney disease and solid cancers.
CNS Activity
Sources: http://adisinsight.springer.com/drugs/800020855
Curator's Comment: In animal models, tesevatinib penetrated the blood-brain barrier and achieved concentrations in the brain that are greater than or equivalent to levels achieved in the blood. Tesevatinib was also found to inhibit the intracranial tumour growth, suggesting its ability to target intracranial tumours
Originator
Sources: http://adisinsight.springer.com/drugs/800020855
Curator's Comment: # Exelixis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17575237 |
0.3 nM [IC50] | ||
Target ID: CHEMBL5147 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17575237 |
1.4 nM [IC50] | ||
Target ID: CHEMBL279 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17575237 |
1.5 nM [IC50] | ||
Target ID: CHEMBL203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17575237 |
0.3 nM [IC50] | ||
Target ID: CHEMBL1824 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17575237 |
16.0 nM [IC50] | ||
Target ID: CHEMBL279 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17575237 |
1.5 nM [IC50] | ||
Target ID: CHEMBL1955 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17575237 |
8.7 nM [IC50] | ||
Target ID: CHEMBL5147 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17575237 |
1.4 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.666 ng/mL/(mg dose) EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30030583 |
4.68 mg/kg single, oral dose: 4.68 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TESEVATINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.28 ng/mL/(mg dose) EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30030583 |
4.68 mg/kg 1 times / day steady-state, oral dose: 4.68 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TESEVATINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.72 ng/mL/(mg dose) EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30030583 |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TESEVATINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
0.611 ng/mL/(mg dose) EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30030583 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TESEVATINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30030583 |
4.68 mg/kg single, oral dose: 4.68 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TESEVATINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
24.6 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30030583 |
4.68 mg/kg 1 times / day steady-state, oral dose: 4.68 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TESEVATINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
34.1 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30030583 |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TESEVATINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.6 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30030583 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TESEVATINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
55.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30030583 |
4.68 mg/kg single, oral dose: 4.68 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TESEVATINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
64.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30030583 |
4.68 mg/kg 1 times / day steady-state, oral dose: 4.68 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TESEVATINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
350 mg 1 times / day multiple, oral (total daily dose) Highest studied dose Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: advanced solid malignancies Sex: M+F Food Status: FASTED Population Size: 5 Sources: |
DLT: QTc prolongation... Dose limiting toxicities: QTc prolongation (grade 3, 2 patients) Sources: |
350 mg 1 times / day multiple, oral (total daily dose) Highest studied dose Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: |
unhealthy n = 41 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 41 Sources: |
Disc. AE: astrointestinal bleed, pneumonia... Other AEs: Pruritus, Dry skin... AEs leading to discontinuation/dose reduction: astrointestinal bleed (grade 3, 1 pt) Other AEs:pneumonia (grade 3, 1 pt) QTc prolongation (grade 3, 1 pt) onychomadesis (grade 2, 1 pt) Pruritus (grade 2, 5%) Sources: Dry skin (grade 2, 2%) Dysgeusia (grade 2, 2%) Mucosal inflammation (grade 2, 2%) Vomiting (grade 2, 2%) Diarrhea (grade 3, 5%) fatigue (grade 3, 2%) |
300 mg 1 times / day multiple, oral (total daily dose) MTD Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 6 Health Status: unhealthy Condition: advanced solid malignancies Sex: M+F Food Status: FASTED Population Size: 6 Sources: |
DLT: pneumonitis... Dose limiting toxicities: pneumonitis (grade 3, 1 pt) Sources: |
300 mg 1 times / day multiple, oral Studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 14 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 14 Sources: |
Disc. AE: QTc prolongation, diarrhea... Other AEs: Nausea, Fatigue... AEs leading to discontinuation/dose reduction: QTc prolongation (grade 3, 1 pt) Other AEs:diarrhea (grade 3, 1 pt) rash (grade 3, 1 pt) gastrointestinal discomfort (grade 1, 1 pt) gastrointestinal bleed (grade 3, 1 pt) Blood creatinine increased (grade 2, 1 pt) Hyperkalemia (grade 2, 1 pt) Nausea (grade 2, 7%) Sources: Fatigue (grade 2, 14%) Anorexia (grade 2, 7%) |
7 mg/kg 1 times / day multiple, oral (unknown) Studied dose Dose: 7 mg/kg, 1 times / day Route: oral Route: multiple Dose: 7 mg/kg, 1 times / day Sources: |
unhealthy n = 2 Health Status: unhealthy Condition: advanced solid malignancies Sex: unknown Food Status: FASTED Population Size: 2 Sources: |
DLT: diarrhea... Dose limiting toxicities: diarrhea (grade 4, 2 patients) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
QTc prolongation | grade 3, 2 patients DLT |
350 mg 1 times / day multiple, oral (total daily dose) Highest studied dose Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: |
unhealthy n = 5 Health Status: unhealthy Condition: advanced solid malignancies Sex: M+F Food Status: FASTED Population Size: 5 Sources: |
onychomadesis | grade 2, 1 pt Disc. AE |
350 mg 1 times / day multiple, oral (total daily dose) Highest studied dose Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: |
unhealthy n = 41 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 41 Sources: |
Dry skin | grade 2, 2% | 350 mg 1 times / day multiple, oral (total daily dose) Highest studied dose Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: |
unhealthy n = 41 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 41 Sources: |
Dysgeusia | grade 2, 2% | 350 mg 1 times / day multiple, oral (total daily dose) Highest studied dose Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: |
unhealthy n = 41 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 41 Sources: |
Mucosal inflammation | grade 2, 2% | 350 mg 1 times / day multiple, oral (total daily dose) Highest studied dose Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: |
unhealthy n = 41 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 41 Sources: |
Vomiting | grade 2, 2% | 350 mg 1 times / day multiple, oral (total daily dose) Highest studied dose Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: |
unhealthy n = 41 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 41 Sources: |
Pruritus | grade 2, 5% | 350 mg 1 times / day multiple, oral (total daily dose) Highest studied dose Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: |
unhealthy n = 41 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 41 Sources: |
QTc prolongation | grade 3, 1 pt Disc. AE |
350 mg 1 times / day multiple, oral (total daily dose) Highest studied dose Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: |
unhealthy n = 41 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 41 Sources: |
astrointestinal bleed | grade 3, 1 pt Disc. AE |
350 mg 1 times / day multiple, oral (total daily dose) Highest studied dose Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: |
unhealthy n = 41 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 41 Sources: |
pneumonia | grade 3, 1 pt Disc. AE |
350 mg 1 times / day multiple, oral (total daily dose) Highest studied dose Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: |
unhealthy n = 41 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 41 Sources: |
fatigue | grade 3, 2% | 350 mg 1 times / day multiple, oral (total daily dose) Highest studied dose Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: |
unhealthy n = 41 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 41 Sources: |
Diarrhea | grade 3, 5% | 350 mg 1 times / day multiple, oral (total daily dose) Highest studied dose Dose: 350 mg, 1 times / day Route: oral Route: multiple Dose: 350 mg, 1 times / day Sources: |
unhealthy n = 41 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 41 Sources: |
pneumonitis | grade 3, 1 pt DLT |
300 mg 1 times / day multiple, oral (total daily dose) MTD Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 6 Health Status: unhealthy Condition: advanced solid malignancies Sex: M+F Food Status: FASTED Population Size: 6 Sources: |
gastrointestinal discomfort | grade 1, 1 pt Disc. AE |
300 mg 1 times / day multiple, oral Studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 14 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 14 Sources: |
Blood creatinine increased | grade 2, 1 pt Disc. AE |
300 mg 1 times / day multiple, oral Studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 14 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 14 Sources: |
Hyperkalemia | grade 2, 1 pt Disc. AE |
300 mg 1 times / day multiple, oral Studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 14 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 14 Sources: |
Fatigue | grade 2, 14% | 300 mg 1 times / day multiple, oral Studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 14 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 14 Sources: |
Anorexia | grade 2, 7% | 300 mg 1 times / day multiple, oral Studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 14 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 14 Sources: |
Nausea | grade 2, 7% | 300 mg 1 times / day multiple, oral Studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 14 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 14 Sources: |
QTc prolongation | grade 3, 1 pt Disc. AE |
300 mg 1 times / day multiple, oral Studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 14 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 14 Sources: |
diarrhea | grade 3, 1 pt Disc. AE |
300 mg 1 times / day multiple, oral Studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 14 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 14 Sources: |
gastrointestinal bleed | grade 3, 1 pt Disc. AE |
300 mg 1 times / day multiple, oral Studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 14 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 14 Sources: |
rash | grade 3, 1 pt Disc. AE |
300 mg 1 times / day multiple, oral Studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 14 Health Status: unhealthy Condition: NSCLC Sex: M+F Food Status: UNKNOWN Population Size: 14 Sources: |
diarrhea | grade 4, 2 patients DLT, Disc. AE |
7 mg/kg 1 times / day multiple, oral (unknown) Studied dose Dose: 7 mg/kg, 1 times / day Route: oral Route: multiple Dose: 7 mg/kg, 1 times / day Sources: |
unhealthy n = 2 Health Status: unhealthy Condition: advanced solid malignancies Sex: unknown Food Status: FASTED Population Size: 2 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. | 2007 Jun 15 |
|
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. | 2008 Apr 15 |
|
New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. | 2010 Jul |
|
EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. | 2012 Feb |
|
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. | 2012 Jan |
|
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. | 2012 May |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22722787
Two dosing schedules were evaluated; in the "intermittent 5 & 9 dosing" cohort, Tesevatinib (XL647) 350 mg for 5 days every 14 days was given; and in the "daily dosing" cohort, XL647 300 mg daily for 28 days was administered. XL647 administered on an intermittent or daily-dosing schedule demonstrated antitumor activity in patients with non-small-cell lung cancer.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17575237
In A431 cells, which express WT EGFR, Tesevatinib reduced cell viability with IC50 values of 13 nmol/L, with 95% confidence intervals of 10 to 15.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1967
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
||
|
FDA ORPHAN DRUG |
802420
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
||
|
NCI_THESAURUS |
C1742
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
||
|
FDA ORPHAN DRUG |
506715
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
||
|
FDA ORPHAN DRUG |
584917
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
BC-18
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
PRIMARY | |||
|
10079
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
PRIMARY | |||
|
Tesevatinib
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
PRIMARY | |||
|
C62496
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
PRIMARY | |||
|
10458325
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
PRIMARY | |||
|
DTXSID201336925
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
PRIMARY | |||
|
F6XM2TN5A1
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
PRIMARY | |||
|
CHEMBL3544983
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
PRIMARY | |||
|
167674
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
PRIMARY | |||
|
300000034419
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
PRIMARY | |||
|
781613-23-8
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
PRIMARY | |||
|
DB11973
Created by
admin on Sat Dec 16 02:09:33 GMT 2023 , Edited by admin on Sat Dec 16 02:09:33 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)